Eosinophilic pustular folliculitis (EPF) is a dermatological disorder characterized by inflammation of the hair follicles and the formation of pustules. The disorder most often occurs in people with a weakened immune response, particularly in HIV patients or those receiving immunosuppressive therapy. Clinical manifestations of EPF include the appearance of a rash in the form of dense papules and pustules, often accompanied by itching and discomfort. Despite its benign nature, the disease can significantly worsen the quality of life of patients, requiring careful monitoring and a comprehensive approach to treatment.
History of the disease and interesting historical facts
The first clinical description of eosinophilic pustular folliculitis dates back to the 1970s, when this disease was isolated from other dermatological pathologies. Initially, EPF was observed mainly in patients with HIV infection, which formed its association with this virus. Over time, the study of EPF has expanded, and links with other forms of immunosuppression, including organ transplantation and chemotherapy, have begun to be identified. In recent decades, the results of numerous studies have allowed a deeper understanding of the pathogenesis of this disease, identifying associated genetic markers and mechanisms of the inflammatory response, which opens new horizons for effective treatment.
Epidemiology
Eosinophilic pustular folliculitis is a rare disease, but its prevalence among people with HIV infection reaches 10-15%. According to the latest data, in the population of patients without immunodeficiency, EPF occurs much less often, with a frequency of about 1 case per 100,000 people. Although exact statistics vary depending on the region, it is known that the disease is most often observed in men, especially between the ages of 20 and 50. Cases are often registered in countries with high HIV incidence.
Genetic predisposition to this disease
Studies suggest that eosinophilic pustular folliculitis may have a genetic component. The focus is on various mutations in immune response-related genes such as IL-4, IL-5, and IL-13, which play a key role in eosinophil activation. Polymorphisms in genes involved in inflammatory regulation have also been observed in patients with EPF, which may predispose to hypereosinophilia. However, further studies are needed to better understand this relationship and identify possible genetic markers to predict disease risk.
Risk factors for the development of this disease
Among the risk factors that contribute to the development of eosinophilic pustular folliculitis are:
- HIV infection and other immunosuppressive conditions;
- Long-term therapy with immunosuppressants;
- Chemotherapy;
- Increased levels of eosinophils in the blood;
- Certain diseases of the blood or connective tissue, such as leukemia.
These factors predispose to increased inflammatory processes and, as a consequence, to the development of EPF. Understanding these risks is of great importance for early diagnosis and prevention of the disease in individuals at high risk.
Diagnosis of this disease
Diagnosis of eosinophilic pustular folliculitis includes several stages:
- Clinical examination and assessment of symptoms such as the presence of pustules, itching and discomfort;
- Laboratory tests: blood test to determine eosinophil levels, HIV serological tests;
- Radiological examinations are not used for EPF, but evaluation of other organs may be required;
- Skin biopsy: To confirm the diagnosis, histological examination of skin samples may be performed, where eosinophilic infiltration will be observed;
- Differential diagnosis: It is necessary to differentiate EPF from other skin diseases such as acne, pustular psoriasis and dermatitis.
A comprehensive examination allows for a reliable diagnosis and appropriate treatment.
Treatment
Treatment of eosinophilic pustular folliculitis requires an individual approach and may include:
- General treatment: avoidance of triggers is recommended (eg, discontinuation of immunosuppressive therapy if possible);
- Pharmacological treatment: systemic corticosteroids and antihistamines to control inflammation and itching;
- Surgical treatment: in most cases these measures are not required, however in rare situations it may be necessary to remove large pustules or perform drainage;
- Other treatments: phototherapy using UV rays during the remission stage.
The effectiveness of treatment directly depends on the identification and elimination of factors contributing to the disease.
List of medications used to treat this disease
Drugs recommended for the treatment of eosinophilic pustular folliculitis include:
- Prednisone;
- Dexamethasone;
- Loratadine;
- Cetirizine;
- Hydroxyzine.
The main groups of drugs are aimed at reducing the inflammatory response and relieving symptoms.
Disease monitoring
Monitoring of eosinophilic pustular folliculitis includes regular dermatological examinations, blood eosinophil monitoring tests, and evaluation of treatment response. The prognosis with adequate therapy is usually favorable, but relapses are possible. Complications may include secondary skin infection and persistent dermal changes, which emphasizes the importance of timely and regular monitoring.
Age-related features of the disease
Eosinophilic pustular folliculitis is most common in adults, especially those with immunosuppression, but can also occur in childhood. In children, the disease has similar symptoms, but can be more severe, requiring special attention from specialists. In older people, the disease lasts longer and relapses are more common due to existing comorbidities.
Questions and Answers
- What is eosinophilic pustular folliculitis? It is a skin condition that appears as pustules around the hair follicles, more common in people with weakened immune systems.
- How is this disease diagnosed? Diagnosis is based on clinical examination, laboratory tests and, if necessary, skin biopsy.
- How is eosinophilic pustular folliculitis treated? Treatment includes corticosteroids and antihistamines, which help control inflammation and itching.
- Can relapses be prevented? Yes, it is important to avoid triggers and see your doctor regularly to monitor your condition.
- Who is at risk? The main risk group is people with HIV, as well as patients receiving immunosuppressive therapy.
Advice from Dr. Oleg Korzhikov
When patients with eosinophilic pustular folliculitis see a doctor, it is important to get accurate information about their condition and possible consequences. I always recommend:
- Undergo regular medical check-ups;
- Monitor your condition and immediately inform your doctor of any changes;
- Avoid stressful situations and maintain a healthy lifestyle to support the immune system.
It is also important not to try to self-medicate, as incorrectly chosen medications can worsen the condition. Consult a specialist to receive the highest quality help.
